血管内皮Krüppel样因子2的抗动脉粥样硬化作用及相关治疗药物研究进展  

Research Progress on the Anti-atherosclerotic Effects of Vascular Endothelial Krüppel-like Factor 2 and Related Therapeutic Drugs

作　　者：滕媛 赵志伟 黄亚萍 牟龙 王子元 张健[2] 殷志琦[1] TENG Yuan;ZHAO Zhiwei;HUANG Yaping;MU Long;WANG Ziyuan;ZHANG Jian;YIN Zhiqi(Department of TCMs Pharmaceuticals,School of Traditional Chinese Pharmacy,China Pharmaceutical University,Nanjing 211198,China;Laboratory of Translational Medicine,Jiangsu Provincial Academy of Traditional Chinese Medicine,Nanjing 210046,China)

机构地区：[1]中国药科大学中药学院中药制剂系,江苏南京211198 [2]江苏省中医药研究院转化医学实验室,江苏南京210046

出　　处：《药学进展》2024年第7期536-547,共12页Progress in Pharmaceutical Sciences

基　　金：江苏省高校“青蓝工程”(No.CPU2018GF05)。

摘　　要：Krüppel样因子2(KLF2)是一种锌指转录因子,通过与目标基因的顺式作用元件结合,正向或负向调控目标基因转录过程。已有研究发现,KLF2高表达于内皮细胞,参与调控涉及细胞分化、炎症反应、氧化应激等多种生物学过程的信号通路,从而缓解血管内皮功能障碍,发挥良好的抗动脉粥样硬化作用。对KLF2抗动脉粥样硬化的功能与机制进行总结,并介绍调控KLF2相关信号通路药物的最新研究进展,旨在为抗动脉粥样硬化药物的开发提供新的策略。Krüppel-like factor 2(KLF2)is a zinc finger transcription factor that regulates the transcription process of the target genes either positively or negatively by binding to the cis-acting elements of these genes.Studies have shown that KLF2 is highly expressed in endothelial cells,and participates in the regulation of various signaling pathways involved in various biological processes,including cell differentiation,inflammatory response,and oxidative stress,thereby alleviating vascular endothelial dysfunction and exerting a beneficial anti-atherosclerotic effect.This article summarizes the anti-atherosclerotic functions and mechanisms of KLF2,and introduces recent advances in research on drugs regulating KLF2-related signaling pathways,aiming to provide new strategies for the development of antiatherosclerotic drugs.

关 键 词：Krüppel样因子2 内皮功能障碍 动脉粥样硬化 治疗靶标 

分 类 号：R972.6[医药卫生—药品]